title: [Diagnosis and therapy of malignant testicular neoplasms].
abstract: For successful treatment of even advanced testicular tumors an accurate histological classification and clinical staging is necessary. The pathohistomorphological classification can be completed by the so-called tumor markers such as alpha-fetoprotein and beta-humanchoriongonadotropin (beta-HCG). These markers are especially valuable in the follow-up of the patient and in the control of the therapeutical effectivity. By optimal diagnosis and therapy seminomas in stage I and II are in 70% to 100%, teratomas in 40% to 80% curable; in the more advanced stages in 30 to 40% a two years relapse-free time can be obtained.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006063:Chorionic Gonadotropin / Q000097:blood; D004407:Dysgerminoma / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D013724:Teratoma / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000970:Antineoplastic Agents; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins
vernacular_title: Diagnostik und Therapie maligner Hodentumoren.